WHO Drug Information, Vol. 20, No. 3, 2006                                                 Recommended INN: List 56



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 56
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in Cumulative List
No. 11, 2004 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 56
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies
par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion
d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la
substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans
la Liste récapitulative No. 11, 2004 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 56
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran
reunidas en Cumulative List No. 11, 2004 (disponible sólo en CD-ROM).




                                                                                                                   203
Recommended INN: List 56                                                    WHO Drug Information, Vol. 20, No. 3, 2006




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 alcaftadinum
 alcaftadine                               11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-imidazo=
                                           [2,1-b][3]benzazepine-3-carbaldehyde

 alcaftadine                               11-(1-méthylpipéridin-4-ylidène)-6,11-dihydro-5H-imidazo=
                                           [2,1-b][3]benzazépine-3-carbaldéhyde

 alcaftadina                               11-(1-metilpiperidin-4-ilideno)-6,11-dihidro-5H-imidazo=
                                           [2,1-b][3]benzazepina-3-carbaldehído

                                           C19H21N3O

                                                                      CH3
                                                                  N




                                                   N     N


                                             O




 amibegronum
 amibegron                                 ethyl {[(7S)-7-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-
                                           5,6,7,8-tetrahydronaphthalen-2-yl]oxy}acetate

 amibégron                                 [[(7S)-7-[[(2R)-2-(3-chlorophényl)-2-hydroxyéthyl]amino]-
                                           5,6,7,8-tétrahydronaphtalén-2-yl]oxy]acétate d’éthyle

 amibegrón                                 [[(7S)-7-[[(2R)-2-(3-clorofenil)-2-hidroxietil]amino]-
                                           5,6,7,8-tetrahidronaftalen-2-il]oxi]acetato de etilo

                                           C22H26ClNO4

                                                       H OH                             O
                                                              H
                                                              N                   O
                                                                                            O   CH3
                                                              H


                                              Cl




204
WHO Drug Information, Vol. 20, No. 3, 2006                                                  Recommended INN: List 56


 antithrombinum alfa
 antithrombin alfa                           human antithrombin-III from the milk of transgenic goats
                                             (glycoform alfa)

 antithrombine alfa                          antithrombine-III humaine extraite du lait de chèvre transgénique
                                             (glycoforme alfa)

 antitrombina alfa                           antitrombina-III humana extraida de la leche de cabra transgénica
                                             (glicoforma alfa)

                                             C2191H3451N583O656S18

                                             HGSPVDICTA        KPRDIPMNPM             CIYRSPEKKA     TEDEGSEQKI
                                             PEATNRRVWE        LSKANSRFAT             TFYQHLADSK     NDNDNIFLSP
                                             LSISTAFAMT              *                QLMEVFKFDT     ISEKTSDQIH
                                                               KLGACNDTLQ
                                                                   *                                     *
                                             FFFAKLNCRL        YRKANKSSKL             VSANRLFGDK     SLTFNETYQD
                                                                                                      *
                                             ISELVYGAKL        QPLDFKENAE             QSRAAINKWV     SNKTEGRITD
                                             VIPSEAINEL        TVLVLVNTIY             FKGLWKSKFS     PENTRKELFY
                                             KADGESCSAS        MMYQEGKFRY             RRVAEGTQVL     ELPFKGDDIT
                                             MVLILPKPEK        SLAKVEKELT             PEVLQEWLDE     LEEMMLVVHM
                                             PRFRIEDGFS        LKEQLQDMGL             VDLFSPEKSK     LPGIVAEGRD
                                             DLYVSDAFHK        AFLEVNEEGS             EAAASTAVVI     AGRSLNPNRV
                                             TFKANRPFLV        FIREVPLNTI             IFMGRVANPC     VK
                                                                     * glycosylation sites
                                                                     * sites de glycosylation
                                                                     * posiciónes de glicosilación




 apadenosonum
 apadenoson                                  methyl trans-4-{3-[6-amino-9-(N-ethyl-β-D-ribofuranosyluronamide)-
                                             9H-purin-2-yl]prop-2-ynyl}cyclohexanecarboxylate

 apadénoson                                  trans-4-[3-[6-amino-9-(N-éthyl-β-D-ribofuranosyluronamide)-
                                             9H-purin-2-yl]prop-2-ynyl]cyclohexanecarboxylate de méthyle

 apadenosón                                  trans-4-[3-[6-amino-9-(N-etil-β-D-ribofuranosiluronamida)-9H-purin-
                                             2-il]prop-2-inil]ciclohexanocarboxilato de metilo

                                             C23H30N6O6

                                                                                  NH2
                                                       O                                N
                                                                             N
                                             H3C
                                                   O
                                                                                  N     N

                                                                       H
                                                             H3 C      N      O
                                                                                  O




                                                                              OH      OH




                                                                                                                   205
Recommended INN: List 56                                  WHO Drug Information, Vol. 20, No. 3, 2006


 aplavirocum
 aplaviroc                 4-(4-{[(3R)-1-butyl-3-[(R)-cyclohexylhydroxymethyl]-2,5-dioxo-
                           1,4,9-triazaspiro[5.5]undecan-9-yl]methyl}phenoxy)benzoic acid

 aplaviroc                 acide 4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexylhydroxyméthyl]-2,5-dioxo-
                           1,4,9-triazaspiro[5.5]undéc-9-yl]méthyl]phénoxy]benzoïque

 aplaviroc                 ácido 4-[4-[[(3R)-1-butil-3-[(R)-ciclohexilhidroximetil]-2,5-dioxo-
                           1,4,9-triazaspiro[5.5]undec-9-il]metil]fenoxi]benzoico

                           C33H43N3O6

                                              O                                  CO2H
                                                      N
                                         HN
                                     H                                O
                                                  N           CH3

                                  H OH O


 avosentanum
 avosentan                 N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-
                           5-methylpyridine-2-sulfonamide

 avosentan                 N-[6-méthoxy-5-(2-méthoxyphénoxy)-2-(pyridin-4-yl)pyrimidin-4-yl]-
                           5-méthylpyridine-2-sulfonamide

 avosentán                 5-metil-N-[6-metoxi-5-(2-metoxifenoxi)-2-(piridin-4-il)pirimidin-
                           4-il]piridina-2-sulfonamida

                           C23H21N5O5S

                                          O O
                                     N     S
                                             NH              OCH3
                                                      O
                           H3C                N

                                                  N   O
                                 N                    CH3


 axitinibum
 axitinib                  N-methyl-2-({3-[(1E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-
                           6-yl}sulfanyl)benzamide

 axitinib                  N-méthyl-2-[[3-[(1E)-2-(pyridin-2-yl)éthényl]-1H-indazol-
                           6-yl]sulfanyl]benzamide

 axitinib                  N-metil-2-[[3-[(1E)-2-(piridin-2-il)etenil]-1H-indazol-6-il]=
                           sulfanil]benzamida




206
WHO Drug Information, Vol. 20, No. 3, 2006                                               Recommended INN: List 56




                                             C22H18N4OS

                                                   H
                                             O     N
                                                       CH3
                                                                   H
                                                       S           N
                                                                       N




                                                                           N




 bosutinibum
 bosutinib                                   4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-
                                             7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

 bosutinib                                   4-[(2,4-dichloro-5-méthoxyphényl)amino]-6-méthoxy-
                                             7-[3-(4-méthylpipérazin-1-yl)propoxy]quinoléine-3-carbonitrile

 bosutinib                                   4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metilpiperazin-
                                             1-il)propoxi]quinolina-3-carbonitrilo

                                             C26H29Cl2N5O3

                                             H3C
                                                   N
                                                           N           O         N


                                                                 H3CO                  CN
                                                                                HN           OCH3


                                                                                Cl           Cl




 brecanavirum
 brecanavir                                  (3R,3aS,6aR)-hexahydrofurano[2,3-b]furan-3-yl
                                             [(2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-
                                             3-hydroxy-1-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl}butan-
                                             2-yl]carbamate

 brécanavir                                  [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-méthylpropyl)amino]-
                                             2-hydroxy-1-[4-[(2-méthylthiazol-4-yl)méthoxy]benzyl]=
                                             propyl]carbamate de (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yle

 brecanavir                                  [(1S,2R)-3-[(1,3-benzodioxol-5-ilsulfonil)(2-metilpropil)amino]-
                                             2-hidroxi-1-[4-[(2-metiltiazol-4-il)metoxi]bencil]propil]carbamato de
                                             (3R,3aS,6aR)-hexahidrofuro[2,3-b]furan-3-ilo




                                                                                                                     207
Recommended INN: List 56                                             WHO Drug Information, Vol. 20, No. 3, 2006


                           C33H41N3O10S2

                                                         O
                                         N

                            H3C              S
                                                     O       H              O O
                                O                H
                           H                                                 S
                                                 O           N             N
                            O                H               H
                                                                 H OH
                                                                 H3C                           O
                                                                                         O
                                                                         CH3


 capeserodum
 capeserod                 5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-
                           3-[1-(2-phenylethyl)piperidin-4-yl]-1,3,4-oxadiazol-2(3H)-one

 capésérod                 5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-
                           3-[1-(2-phényléthyl)pipéridin-4-yl]-1,3,4-oxadiazol-2(3H)-one

 capeserod                 5-(8-amino-7-cloro-2,3-dihidro-1,4-benzodioxin-5-il)-
                           3-[1-(2-feniletil)piperidin-4-il]-1,3,4-oxadiazol-2(3H)-ona

                           C23H25ClN4O4


                                    O            O
                                                             O       O
                           H2N
                                                                 N
                                                             N
                                    Cl                                         N




 casopitantum
 casopitant                (2R,4S)-4-(4-acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)=
                           phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-
                           1-carboxamide

 casopitant                (2R,4S)-4-(4-acétylpipérazin-1-yl)-N-[(1R)-1-[3,5-bis(trifluorométhyl)=
                           phényl]éthyl]-2-(4-fluoro-2-méthylphényl)-N-méthylpipéridine-
                           1-carboxamide

 casopitant                (2R,4S)-4-(4-acetilpiperazin-1-il)-N-[(1R)-1-[3,5-bis(trifluorometil)=
                           fenil]etil]-2-(4-fluoro-2-metilfenil)-N-metilpiperidin-1-carboxamida

                           C30H35F7N4O2

                                                                                         CF3
                               O                         H
                                         N           N                     CH3
                           H3C                                       N     N
                                                                                               CF3
                                                                 H     O       H   CH3
                                                                     CH3

                                                     F




208
WHO Drug Information, Vol. 20, No. 3, 2006                                                 Recommended INN: List 56




 celivaronum
 celivarone                                  isopropyl 2-butyl-3-{4-[3-(dibutylamino)propyl]benzoyl}-1-benzofuran-
                                             5-carboxylate

 célivarone                                  2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]benzofurane-
                                             5-carboxylate de 1-méthyléthyle

 celivarona                                  2-butil-3-{4-[3-(dibutilamino)propil]benzoil}-1-benzofurano-
                                             5-carboxilato de isopropilo

                                             C34H47NO4

                                             H3C                 O
                                                                                                CH3
                                                        O
                                                                                       N           CH3


                                                                     O
                                                                           CH3
                                                                O
                                                                     H3C



 cevoglitazarum
 cevoglitazar                                (2R)-1-{[4-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}=
                                             methoxy)phenyl]sulfonyl}-2,3-dihydro-1H-indole-2-carboxylic acid

 cévoglitazar                                acide (2R)-1-[[4-[[5-méthyl-2-[4-(trifluorométhyl)phényl]oxazol-4-yl]=
                                             méthoxy]phényl]sulfonyl]-2,3-dihydro-1H-indole-2-carboxylique

 cevoglitazar                                ácido (2R)-1-[[4-[[5-metil-2-[4-(trifluorometil)fenil]oxazol-
                                             4-il]metoxi]fenil]sulfonil]-2,3-dihidro-1H-indol-2-carboxílico

                                             C27H21F3N2O6S

                                                                                     O O H CO H
                                                                                             2
                                                                                      S
                                                                                        N

                                                                N
                                                                           O
                                             F3C
                                                                O        CH3



 darapladibum
 darapladib                                  N-[2-(diethylamino)ethyl]-2-(2-{[(4-fluorophenyl)methyl]sulfanyl}-
                                             4-oxo-4,5,6,7-tetrahydro-1H-cyclopentapyrimidin-1-yl)-
                                             N-{[4'-(trifluoromethyl)biphenyl-4-yl]methyl}acetamide

 darapladib                                  N-[2-(diéthylamino)éthyl]-2-[2-[(4-fluorobenzyl)sulfanyl]-4-oxo-
                                             4,5,6,7-tétrahydro-1H-cyclopentapyrimidin-1-yl]-
                                             N-[[4'-(trifluorométhyl)biphényl-4-yl]méthyl]acétamide

 darapladib                                  N-[2-(dietilamino)etil]-2-[2-[(4-fluorobencil)sulfanil]-4-oxo-
                                             4,5,6,7-tetrahidro-1H-ciclopentapirimidin-1-il]-N-[[4'-(trifluorometil)=
                                             bifenil-4-il]metil]acetamida




                                                                                                                        209
Recommended INN: List 56                                    WHO Drug Information, Vol. 20, No. 3, 2006


                           C36H38F4N4O2S


                                     O
                                                           O
                            F            N        N
                                                               N
                                             S

                                             H3C           N       CH3
                                                                                    CF3



 dasatinibum
 dasatinib                 N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-
                           2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide

 dasatinib                 N-(2-chloro-6-méthylphényl)-2-[[6-[4-(2-hydroxyéthyl)pipérazin-1-yl]-
                           2-méthylpyrimidin-4-yl]amino]thiazole-5-carboxamide

 dasatinib                 N-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)piperazin-1-il]-
                           2-metilpirimidin-4-il]amino]tiazol-5-carboxamida

                           C22H26ClN7O2S

                                     CH3                                           OH
                                        O                                    N
                                                           H
                                                 S         N             N
                                     N
                                     H
                                Cl                    N        N     N

                                                                   CH3



 denagliptinum
 denagliptin               (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-
                           4-fluoropyrrolidine-2-carbonitrile

 dénagliptine              (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophényl)propanoyl]-
                           4-fluoropyrrolidine-2-carbonitrile

 denagliptina              (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorofenil)propanoil]-
                           4-fluoropirrolidina-2-carbonitrilo

                           C20H18F3N3O

                                         F




                                                 O         H CN

                                                       N
                                         H       NH2
                            F
                                                               H
                                                           F




210
WHO Drug Information, Vol. 20, No. 3, 2006                                               Recommended INN: List 56


 denosumabum*
 denosumab                                   immunoglobulin G2, anti-(human tumor necrosis factor ligand
                                             superfamily member 11 (human osteoclast differentiation factor))
                                             (human monoclonal AMG162 heavy chain), disulfide with human
                                             monoclonal AMG162 light chain, dimer
                                                                                  ème
 dénosumab                                   immunoglobuline G2, anti-(11        membre de la superfamille des
                                             ligands du facteur de nécrose tumorale (TNF) humain (facteur de
                                             différentiation de l'ostéoclaste)), dimère du disulfure entre la chaîne
                                             lourde et la chaîne légère de l’anticorps monoclonal humain
                                             AMG162

 denosumab                                   inmunoglobulina G2, anti-(miembro nº 11 de la superfamilia de
                                             ligandos del factor de necrosis tumoral (TNF) humano (factor de
                                             diferenciación de osteoclastos)), dímero del disulfuro entre la
                                             cadena pesada y la cadena ligera del anticuerpo monoclonal
                                             humano AMG162

                                             C6404H9908N1724O2004S50




 dexamethasoni cipecilas
 dexamethasone cipecilate                    9-fluoro-11β-hydroxy-16α-methyl-3,20-dioxopregna-1,4-diene-
                                             17,21-diyl 21-cyclohexanecarboxylate 17-cyclopropanecarboxylate

 cipécilate de dexaméthasone                 21-cyclohexanecarboxylate et 17-cyclopropanecarboxylate de
                                             9-fluoro-11β-hydroxy-16α-méthyl-3,20-dioxoprégna-1,4-diène-
                                             17,21-diyle

 cipecilato de dexametasona                  17-ciclopropanocarboxilato 9-fluoro-11β-hidroxi-16α-metil-
                                             3,20-dioxopregna-1,4-dieno-17,21-diil 21-ciclohexanecarboxilato

                                             C33H43FO7

                                                                                  O

                                                                              O
                                                                      O           O
                                                          H       CH3
                                                     HO                   O
                                                       CH3    H            CH3
                                                                          H
                                                          F       H
                                             O



 diaplasininum
 diaplasinin                                 1-benzyl-3-pentyl-2-{6-[(1H-tetrazol-5-yl)methoxy]naphthalen-2-yl}-
                                             1H-indole

 diaplasinine                                1-benzyl-3-pentyl-2-[6-(1H-tétrazol-5-ylméthoxy)naphtalén-2-yl]-
                                             1H-indole

 diaplasinina                                1-bencil-3-pentil-2-{6-[(1H-tetrazol-5-il)metoxi]naftalen-2-il}-1H-indol




                                                                                                                       211
Recommended INN: List 56                               WHO Drug Information, Vol. 20, No. 3, 2006


                           C32H31N5O

                                                                       HN N
                                                                                 N
                                                                 O
                                                                             N

                                       N



                                                           CH3



 dilopetinum
 dilopetine                2-[(2-methyl-1H-pyrazol-3-yl)(thiophen-2-yl)methoxy]-
                           N,N-dimethylethanamine

 dilopétine                N,N-diméthyl-2-[(RS)-(1-méthyl-1H-pyrazol-5-yl)(thiophén-2-yl)=
                           méthoxy]éthanamine

 dilopetina                2-[(2-metil-1H-pirazol-3-il)(tiofen-2-il)metoxi]-N,N-dimetiletanamina

                           C13H19N3OS


                                   S
                                       H         CH3        and enantiomer
                                                 N          et énantiomère
                                       O             CH3    y enantiómero

                            N N
                                   CH3



 disomotidum
 disomotide                [186-L-methionine]melanocyte protein Pmel 17 (human
                           melanoma-associated ME20 antigen)-(185-193)-peptide

 disomotide                [186-L-méthionine]protéine Pmel 17 du mélanocyte humain
                           (antigène ME20 associé au mélanome humain)-(185-193)-peptide

 disomotida                [186-L-metionina]proteína Pmel 17 de melanocitos humanos
                           (antígeno ME20 asociado al melanoma humano)-(185-193)-péptido

                           C47H74N10O14S

                           H Ile   Met     Asp   Gln   Val       Pro   Phe       Ser   Val OH




 dutacatibum
 dutacatib                 N-({2-cyano-4-[(2,2-dimethylpropyl)amino]pyrimidin-5-yl}methyl)-
                           4-(4-methylpiperazin-1-yl)benzamide

 dutacatib                 N-[[2-cyano-4-[(2,2-diméthylpropyl)amino]pyrimidin-5-yl]méthyl]-
                           4-(4-méthylpipérazin-1-yl)benzamide

 dutacatib                 N-[[2-ciano-4-[(2,2-dimetilpropil)amino]pirimidin-5-il]metil]-
                           4-(4-metilpiperazin-1-il)benzamida




212
WHO Drug Information, Vol. 20, No. 3, 2006                                                     Recommended INN: List 56


                                             C23H31N7O

                                             H3C
                                                    N
                                                             N                         N       CN
                                                                                  H
                                                                                  N        N
                                                                                               CH3
                                                                             O        HN         CH3
                                                                                                CH3



 eltrombopagum
 eltrombopag                                 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-
                                             4H-pyrazol-4-ylidene]diazanyl}-2'-hydroxybiphenyl-3-carboxylic acid

 eltrombopag                                 acide 3'-[(2Z)-2-[1-(3,4-diméthylphényl)-3-méthyl-5-oxo-1,5-dihydro-
                                             4H-pyrazol-4-ylidène]diazanyl]-2'-hydroxybiphényl-3-carboxylique

 eltrombopag                                 ácido 3'-{(2Z)-2-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-dihidro-
                                             4H-pirazol-4-ilideno]diazanil}-2'-hidroxibifenil-3-carboxílico

                                             C25H22N4O4

                                                   H3C
                                                                  N                        CO2H
                                                                       N
                                                    N                  H
                                                        N                    OH
                                                                  O




                                                            CH3
                                             H3C



 eprodisatum
 eprodisate                                  propane-1,3-disulfonic acid

 éprodisate                                  acide propane-1,3-disulfonique

 eprodisato                                  ácid propano-1, 3-disulfónico

                                             C3H8O6S2

                                             HO3S                     SO3H




 fimasartanum
 fimasartan                                  2-({2-butyl-4-methyl-6-oxo-1-{[2'-(1H-tetrazol-5-yl)biphenyl-
                                             4-yl]methyl}-1,6-dihydropyrimidin-5-yl})-N,N-dimethylthioacetamide

 fimasartan                                  2-[2-butyl-4-méthyl-6-oxo-1-[[2'-(1H-tétrazol-5-yl)biphényl-
                                             4-yl]méthyl]-1,6-dihydropyrimidin-5-yl]-N,N-diméthylthioacétamide

 fimasartán                                  2-({2-butil-4-metil-6-oxo-1-{[2'-(1H-tetrazol-5-il)bifenil-4-il]metil}-
                                             1,6-dihidropirimidin-5-il})-N,N-dimetiltioacetamida




                                                                                                                       213
Recommended INN: List 56                                            WHO Drug Information, Vol. 20, No. 3, 2006


                            C27H31N7OS

                                  CH3                   O                           N   N
                                  N                                               HN    N
                            H3C                             N
                                          S
                                          H3C           N
                                                                            CH3


 fosaprepitantum
 fosaprepitant              (3-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-
                            3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo-4,5-dihydro-
                            1H-1,2,4-triazol-1-yl)phosphonic acid

 fosaprépitant              acide [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy]-
                            3-(4-fluorophényl)morpholin-4-yl]méthyl]-5-oxo-4,5-dihydro-
                            1H-1,2,4-triazol-1-yl]phosphonique

 fosaprepitant              ácido [3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi]-
                            3-(4-fluorofenil)morfolin-4-il]metil]-5-oxo-4,5-dihidro-1H-1,2,4-triazol-
                            1-il]fosfónico

                            C23H22F7N4O6P

                             HO       O
                                  P
                            HO
                                      N N                       O       H   CH3
                                                                    H
                             O                      N                                   CF3
                                      N                             O
                                      H
                                                            H

                                                                                  CF3
                                            F


 fospropofolum
 fospropofol                dihydrogen (2,6-diisopropylphenoxy)methyl phosphate

 fospropofol                dihydrogénophosphate de [2,6-bis(1-méthyléthyl)phénoxy]méthyle

 fospropofol                dihidrógenofosfato de [2,6-bis(1-metiletil)fenoxi]metilo

                            C13H21O5P

                                                HO OH
                                                    P
                                                O           O

                                  CH3       O       CH3

                            H3C                             CH3




 gabapentinum enacarbilum
 gabapentin enacarbil       (1-{[({(1RS)-1-[(2-methylpropanoyl)oxy]ethoxy}carbonyl)amino]=
                            methyl}cyclohexyl)acetic acid

 gabapentine enacarbil      acide [1-[[[[(1RS)-1-[(2-méthylpropanoyl)oxy]éthoxy]carbonyl]=
                            amino]méthyl]cyclohexyl]acétique



214
WHO Drug Information, Vol. 20, No. 3, 2006                                                      Recommended INN: List 56




 gabapentina enacarbilo                      ácido (1-{[({(1RS)-1-[(2-metilpropanoil)oxi]etoxi}carbonil)amino]=
                                             metil}ciclohexil)acético

                                             C16H27NO6

                                                          O   H   CH3 O
                                             H 3C                                              and enantiomer
                                                              O    O       N              CO2H et énantiomère
                                                                           H                   y enantiómero
                                                    CH3




 goxalapladibum
 goxalapladib                                2-{2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1,8-naphthyridin-1(4H)-yl}-
                                             N-[1-(2-methoxyethyl)piperidine-4-yl]-N-{[4'-(trifluoromethyl)biphenyl-
                                             4-yl]methyl}acetamide

 goxalapladib                                2-[2-[2-(2,3-difluorophényl)éthyl]-4-oxo-1,8-naphtyridin-1(4H)-yl]-
                                             N-[1-(2-méthoxyéthyl)pipéridin-4-yl]-N-[[4'-(trifluorométhyl)biphényl-
                                             4-yl]méthyl]acétamide

 goxalapladib                                2-[2-[2-(2,3-difluorofenil)etil]-4-oxo-1,8-naftiridin-1(4H)-il]-
                                             N-[1-(2-metoxietil)piperidin-4-il]-N-[[4'-(trifluorometil)bifenil-
                                             4-il]metil]acetamida

                                             C40H39F5N4O3



                                                          O            N
                                                                           O
                                                                   N
                                                                               N

                                             F
                                                      F
                                                                               N                        CF3
                                                                                      O
                                                                                          CH3



 incyclinidum
 incyclinide                                 (4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-
                                             1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

 incyclinide                                 (4aS,5aR,12aS)-3,10,12,12a-tétrahydroxy-1,11-dioxo-
                                             1,4,4a,5,5a,6,11,12a-octahydrotétracène-2-carboxamide

 inciclinida                                 (4aS,5aR,12aS)-3,10,12,12a-tetrahidroxi-1,11-dioxo-
                                             1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida

                                             C19H17NO7

                                                 OH       O       OH O         O
                                                                    OH
                                                                                    NH2

                                                                               OH
                                                              H    H




                                                                                                                      215
Recommended INN: List 56                             WHO Drug Information, Vol. 20, No. 3, 2006


 indantadolum
 indantadol                2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide

 indantadol                2-[(2,3-dihydro-1H-indén-2-yl)amino]acétamide

 indantadol                2-[(2,3-dihidro-1H-inden-2-il)amino]acetamida

                           C11H14N2O

                                              O
                                        H
                                        N
                                                  NH2




 ipilimumabum*
 ipilimumab                immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human
                           γ1-chain), disulfide with human κ-chain, dimer

 ipilimumab                immunoglobuline G1, anti-(antigène CTLA-4 humain), dimère du
                           disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal
                           humain

 ipilimumab                inmunoglobulina G1, anti-(antígeno CTLA-4 humano), dímero del
                           disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal
                           humano

                           C6472H9972N1732O2004S40



 iratumumabum*
 iratumumab                immunoglobulin G1, anti-(Tumor necrosis factor ligand superfamily
                           member 8 (CD30 ligand)) (human monoclonal MDX-060 heavy
                           chain), disulfide with human monoclonal MDX-060 light chain, dimer
                                                            ème
 iratumumab                immunoglobuline G1, anti-(8 membre de la superfamille des
                           ligands du facteur de nécrose tumoral (TNF) humain), dimère du
                           disulfure entre les chaînes lourde et légère de l'anticorps monoclonal
                           humain NDX-060
                                                        º
 iratumumab                inmunoglobulina G1, anti-(8 miembro de la superfamilia de ligandos
                           del factor de necrosis tumoral (TNF) humano ), dímero del disulfuro
                           entre la cadena pesada y la cadena ligera del anticuerpo monoclonal
                           humano NDX-060

                           C6358H9830N1682O1992S38




 larotaxelum
 larotaxel                 1-hydroxy-9-oxo-5β,20-epoxy-7β,19-cyclotax-11-ene-
                           2α,4,10β,13α-tetrayl 4,10-diacetate 2-benzoate 13-{(2R,3S)-3-[(tert-
                           butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}




216
WHO Drug Information, Vol. 20, No. 3, 2006                                                          Recommended INN: List 56


 larotaxel                                   (-)-7,12a-diacétate, 1-benzoate et 4-[(2R,3S)-3-[[(1,1-
                                             diméthyléthoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate]
                                             (1S,2S,4S,5E,7R,8aR,9aS,10aR,12aS,12bR)-2-hydroxy-5,13,13-
                                             triméthyl-8-oxo-1,3,4,7,8,9,9a,10,10a,12b-décahydro-2,6-méthano-
                                             2H-cyclodeca[3,4]cyclopropa[4,5]benzo[1,2-b]oxète-1,4,7,12a(12H)-
                                             tétrayle

 larotaxel                                   4,10-diacetato 2-benzoato 13-{(2R,3S)-3-[(terc-butoxicarbonil)=
                                             amino]-2-hidroxi-3-fenilpropanoato} de1-hidroxi-9-oxo-5β,20-epoxi-
                                             7β,19-ciclotax-11-eno-2α,4,10β,13α-tetrailo

                                             C45H53NO14

                                                                              CH3

                                                                          O       O     O
                                                                    H3C       H                     H
                                                       HO H
                                                                    O                 CH3
                                                                                                H       H
                                                                    H                 CH3
                                                  HN    H       O
                                                            O                               O           O
                                                                              OH        H
                                                    O
                                                          CH3                         O O       CH3
                                                          CH3
                                                 H3C                              O



 lisdexamfetaminum
 lisdexamfetamine                            (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide

 lisdexamfétamine                            (2S)-2,6-diamino-N-[(1S)-1-méthyl-2-phényléthyl]hexanamide

 lisdexanfetamina                            (2S)-2,6-diamino-N-[(1S)-2-fenil-1-metiletil]hexanamida

                                             C15H25N3O

                                                                    H NH2
                                                                H
                                                                N
                                                                                        NH2
                                                        H CH3 O




 lodenafili carbonas
 lodenafil carbonate                         bis(2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-
                                             1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenylsulfonyl]piperazin-1-yl}ethyl)
                                             carbonate

 lodénafil carbonate                         carbonate de 2-[4-[[4-éthoxy-3-(1-méthyl-7-oxo-3-propyl-6,7-dihydro-
                                             1H-pyrazolo[4,3-d]pyrimidin-5-yl)phényl]sulfonyl]pipérazin-1-yl]éthyle

 carbonato de lodenafilo                     carbonato de bis(2-{4-[4-etoxi-3-(1-metil-7-oxo-3-propil-4,7-dihidro-
                                             1H-pirazolo[4,3-d]pirimidin-5-il)fenilsulfonil]piperazin-1-il}etil)




                                                                                                                         217
Recommended INN: List 56                                     WHO Drug Information, Vol. 20, No. 3, 2006


                           C47H62N12O11S2

                                                                          O         CH3
                                                                                   N
                                                      O O            HN
                                                                                       N
                                                       S
                                                     N                    N
                                           N
                                 O                                    O       CH3          CH3
                           O
                                 O                                    O       CH3          CH3
                                           N
                                                     N                    N
                                                         S
                                                                                       N
                                                     O O             HN
                                                                                   N

                                                                          O         CH3




 masilukastum
 masilukast                3-[(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}phenyl)=
                           methyl]-1-methyl-N-[(2R)-4,4,4-trifluoro-2-methylbutyl]-1H-indole-
                           5-carboxamide

 masilukast                3-[2-méthoxy-4-[[(2-méthylphényl)sulfonyl]carbamoyl]benzyl]-
                           1-méthyl-N-[(2R)-4,4,4-trifluoro-2-méthylbutyl]-1H-indole-
                           5-carboxamide

 masilukast                1-metil-3-[(4-{[(2-metilfenil)sulfonil]carbamoil}fenil)metil-2-metoxi]-
                           N-[(2R)-4,4,4-trifluoro-2-metilbutil]-1H-indol-5-carboxamida

                           C31H32F3N3O5S

                                                                          O    O O         CH3
                                               H3C
                                                         H3CO                       S
                                                     N                         N
                                                                               H



                           F3C

                                 H CH N          O
                                     3 H




 mavacoxibum
 mavacoxib                 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]=
                           benzenesulfonamide

 mavacoxib                 4-[5-(4-fluorophényl)-3-(trifluorométhyl)-1H-pyrazol-1-yl]=
                           benzènesulfonamide

 mavacoxib                 4-[5-(4-fluorofenil)-3-(trifluorometil)-1H-pirazol-1-il]=
                           bencenesulfonamida




218
WHO Drug Information, Vol. 20, No. 3, 2006                                                Recommended INN: List 56


                                             C16H11F4N3O2S

                                              F

                                                                O O
                                                                  S
                                                                      NH2

                                                     N
                                                     N
                                             F3C


 nilotinibum
 nilotinib                                   4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-
                                             3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide

 nilotinib                                   4-méthyl-N-[3-(4-méthyl-1H-imidazol-1-yl)-5-(trifluorométhyl)phényl]-
                                             3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide

 nilotinib                                   4-metil-N-[3-(4-metil-1H-imidazol-1-il)-5-(trifluorometil)fenil]-
                                             3-{[4-(piridin-3-il)pirimidin-2-il]amino}benzamida

                                             C28H22F3N7O

                                                               CF3

                                                                            O
                                                                                      H
                                                                                      N     N            N
                                             H3C         N              N
                                                                        H
                                                     N                                  N
                                                                                      CH3


 nimotuzumabum*
 nimotuzumab                                 immunoglobulin G1, anti-(humanized mouse monoclonal hR3 ß1
                                             chain anti-human epidermal growth factor receptor), disulfide with
                                             humanized mouse monoclonal hR3 κ-chain, dimer

 nimotuzumab                                 immunoglobuline G1, anti-(récepteur du facteur de croissance des
                                             cellules de l’épiderme humain), dimère du disulfure entre la chaîne
                                             β1 et la chaîne κ de l’anticorps monoclonal de souris humanisé hR3

 nimotuzumab                                 inmunoglobulina G1, anti-(receptor del factor de crecimiento de
                                             células de epidermis humana), dímero del disulfuro entre la cadena
                                             β1 y la cadena κ del anticuerpo monoclonal hR3 humanizado de
                                             ratón

                                             C6566H10082N1746O2056S40



 obatoclaxum
 obatoclax                                   2-{2-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-3-methoxy-2H-pyrrol-
                                             5-yl}-1H-indole

 obatoclax                                   2-[2-[(3,5-diméthyl-1H-pyrrol-2-yl)méthylidène]-3-méthoxy-2H-pyrrol-
                                             5-yl]-1H-indole

 obatoclax                                   2-[2-[(3,5-dimetil-1H-pirrol-2-il)metilideno]-3-metoxi-2H-pirrol-5-il]-
                                             1H-indol




                                                                                                                       219
Recommended INN: List 56                                WHO Drug Information, Vol. 20, No. 3, 2006


                           C20H19N3O

                                                       H3C
                                       NH
                                             N                        CH3
                                                                  N
                                                                  H

                                                  OCH3


 ocrelizumabum*
 ocrelizumab               immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse
                           monoclonal 2H7 γ1-chain), disulfide with human-mouse monoclonal
                           2H7 κ-chain, dimer

 ocrélizumab               immunoglobuline G1, anti-(antigène CD20 humain), dimère du
                           disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal
                           de souris humanisé 2H7

 ocrelizumab               inmunoglobulina G1, anti-(antígeno) CD20 humano) dímero del
                           disulfuro entre la cadena γ1 del anticuerpo monoclonal 2H7 hombre-
                           ratón, y la cadena-κ del anticuerpo monoclonal 2H7 hombre-ratón

                           C6494H9978N1718O2014S46


 oglemilastum
 oglemilast                N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-[(methylsulfonyl)=
                           amino]dibenzo[b,d]furan-1-carboxamide

 oglémilast                N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-[(methylsulfonyl)=
                           amino]dibenzo[b,d]furan-1-carboxamide

 oglemilast                N-(3,5-dicloropiridin-4-il)-4-(difluorometoxi)-8-[(metilsulfonil)=
                           amino]dibenzo[b,d]furano-1-carboxamida

                           C20H13Cl2F2N3O5S

                                                  CH3
                                        HN    S
                                                  O
                                             O
                                                  Cl
                                              O                   N
                                   O
                               F                   N
                                                   H
                                                             Cl
                           F       O


 olaparibum
 olaparib                  4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-
                           4-fluorophenyl)methyl]phthalazin-1(2H)-one

 olaparib                  1-(cyclopropylcarbonyl)-4-[2-fluoro-5-[(4-oxo-3,4-dihydrophtalazin-
                           1-yl)méthyl]benzoyl]pipérazine

 olaparib                  1-(ciclopropilcarbonil)-4-[2-fluoro-5-[(4-oxo-3,4-dihidroftalazin-
                           1-il)metil]benzoil]piperazina




220
WHO Drug Information, Vol. 20, No. 3, 2006                                                                Recommended INN: List 56


                                             C24H23FN4O3

                                                                               O

                                                                                    N
                                                         N                                    N
                                             O       N                         F
                                                     H
                                                                                                   O


 orvepitantum
 orvepitant                                  (2R,4S)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-
                                             2-methylphenyl)-N-methyl-4-[(8aS)-6-oxohexahydro-1H-pyrrolo=
                                             [1,2-a]pyrazin-2-yl]piperidine-1-carboxamide

 orvépitant                                  (2R,4S)-N-[(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthyl]-2-(4-fluoro-
                                             2-méthylphényl)-N-méthyl-4-[(8aS)-6-oxohexahydropyrrolo=
                                             [1,2-a]pyrazin-2(1H)-yl]pipéridine-1-carboxamide

 orvepitant                                  (2R,4S)-N-[(1R)-1-[3,5-bis(trifluorometil)fenil]etill]-2-(4-fluoro-
                                             2-metilfenil)-N-metil-4-[(8aS)-6-oxohexahidropirrolo[1,2-a]pirazin-
                                             2(1H)-il]piperidina-1-carboxamida

                                             C31H35F7N4O2

                                                         H                                          CF3
                                                                   H
                                                     N         N                     CH3
                                             O
                                                                           N         N
                                                                                                           CF3
                                                                         H     O         H    CH3
                                                                             CH3

                                                               F


 ovemotidum
 ovemotide                                   [264-L-valine]melanocyte protein Pmel 17 (human
                                             melanoma-associated ME20 antigen)-(256-264)-peptide

 ovémotide                                   [264-L-valine]protéine Pmel 17 du mélanocyte humain (antigène
                                             ME20 associé au mélanome humain)-(256-264)-peptide

 ovemotida                                   [264-L-valina]proteína Pmel 17 de melanocitos humanos (antígeno
                                             ME20 asociado al melanoma humano)-(256-264)-péptido

                                             C46H71N9O14

                                             H Tyr       Leu       Glu   Pro       Gly       Pro    Val   Thr    Val OH


 ozarelixum
 ozarelix                                    N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-
                                                                                                   6
                                             3-(pyridin-3-yl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N -carbamoyl-
                                             D-lysyl-L-2-aminohexanoyl-L-arginyl-L-prolyl-D-alaninamide

 ozarélix                                    N-acétyl-3-(naphthalén-2-yl)-D-alanyl-4-chloro-D-phénylalanyl-
                                                                                                   6
                                             3-(pyridin-3-yl)-D-alanyl-L-séryl-N-méthyl-L-tyrosyl-N -carbamoyl-
                                             D-lysyl-L-2-aminohexanoyl-L-arginyl-L-prolyl-D-alaninamide




                                                                                                                               221
Recommended INN: List 56                                        WHO Drug Information, Vol. 20, No. 3, 2006


 ozarelix                  N-acetil-3-(naftalen-2-il)-D-alanil-4-cloro-D-fenilalanil-3-(piridin-3-il)-
                                                               6
                           D-alanil-L-seril-N-metil-L-tirosil-N -carbamoil-D-lisil-
                           L-2-aminohexanoil-L-arginil-L-prolil-D-alaninamida

                           C72H96ClN17O14



                                                                  N                     CH3
                                                                           O    NH2
                                                 Cl                    CH3
                           H3C
                                      3         4           3         N    N6     3
                                    D-Ala     D-Phe       D-Ala   Ser Tyr D-Lys D-Ala    Arg Pro D-Ala NH2
                                O



 paquinimodum
 paquinimod                N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-
                           3-carboxamide

 paquinimod                N,5-diéthyl-4-hydroxy-1-méthyl-2-oxo-N-phényl-
                           1,2-dihydroquinoléine-3-carboxamide

 paquinimod                N,5-dietil-4-hidroxi-1-metil-2-oxo-N-fenil-1,2-dihidroquinolina-
                           3-carboxamida

                           C21H22N2O3

                                          CH3
                                          N      O          CH3

                                                      N

                                          OH     O
                           H3C




 parogrelilum
 parogrelil                4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(pyridin-3-ylmethyl)=
                           amino]pyridazin-3(2H)-one

 parogrélil                4-bromo-6-[3-(4-chlorophényl)propoxy]-5-[(pyridin-3-ylméthyl)=
                           amino]pyridazin-3(2H)-one

 parogrelilo               4-bromo-6-[3-(4-clorofenil)propoxi]-5-[(piridin-3-ilmetil)=
                           amino]piridazin-3(2H)-ona

                           C19H18BrClN4O2

                                                           O
                                                                      Br
                                                 HN
                           Cl                         N
                                                                      N
                                                                      H
                                                           O
                                                                           N




222
WHO Drug Information, Vol. 20, No. 3, 2006                                                            Recommended INN: List 56


 pazopanibum
 pazopanib                                   5-({4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-
                                             2-yl}amino)-2-methylbenzenesulfonamide

 pazopanib                                   5-[[4-[(2,3-diméthyl-2H-indazol-6-yl)méthylamino]pyrimidin-
                                             2-yl]amino]-2-méthylbenzènesulfonamide

 pazopanib                                   5-({4-[(2,3-dimetil-2H-indazol-6-il)metilamino]pirimidin-2-il}amino)-
                                             2-metilbencenosulfonamida

                                             C21H23N7O2S

                                                                                 CH3
                                                                 H
                                                                 N       N       N           N
                                                                                                  N    CH3
                                                                     N
                                             H3C
                                                   O       S                                  CH3
                                                               NH2
                                                       O



 relacatibum
 relacatib                                   N-[(1S)-3-methyl-1-{[(4S,7R)-7-methyl-3-oxo-1-(pyridin-2-ylsulfonyl)=
                                             hexahydro-1H-azepin-4-yl]carbamoyl}butyl]-1-benzofuran-
                                             2-carboxamide

 rélacatib                                   N-[(1S)-3-méthyl-1-[[(4S,7R)-7-méthyl-3-oxo-1-(pyridin-2-ylsulfonyl)=
                                             hexahydro-1H-azépin-4-yl]carbamoyl]butyl]benzofurane-
                                             2-carboxamide

 relacatib                                   N-[(1S)-3-metil-1-{[(4S,7R)-7-metil-3-oxo-1-(piridin-2-ilsulfonil)=
                                             hexahidro-1H-azepin-4-il]carbamoil}butil]-1-benzofuran-
                                             2-carboxamida

                                             C27H32N4O6S

                                                                         CH3
                                                                H3C
                                                                O H                          CH3
                                                                                 H
                                                       O                         N            H
                                                                     N
                                                                     H           H       N
                                                                             O               S         N
                                                                                     O   O O



 rilapladibum
 rilapladib                                  2-(2-{[(2,3-difluorophenyl)methyl]sulfanyl}-4-oxoquinolin-1(4H)-yl)-
                                             N-[1-(2-methoxyethyl)piperidin-4-yl]-N-{[4'-(trifluoromethyl)biphenyl-
                                             4-yl]methyl}acetamide

 rilapladib                                  2-[2-[(2,3-difluorobenzyl)sulfanyl]-4-oxoquinoléin-1(4H)-yl]-
                                             N-[1-(2-méthoxyéthyl)pipéridin-4-yl]-N-[[4'-(trifluorométhyl)biphényl-
                                             4-yl]méthyl]acétamide

 rilapladib                                  2-[2-[(2,3-difluorobencil)sulfanil]-4-oxoquinolin-1(4H)-il]-
                                             N-[1-(2-metoxietil)piperidin-4-il]-N-[[4'-(trifluorometil)bifenil-
                                             4-il]metil]acetamida




                                                                                                                           223
Recommended INN: List 56                              WHO Drug Information, Vol. 20, No. 3, 2006


                           C40H38F5N3O3S



                                      O
                                                     O
                                               N
                                                         N
                                           S
                           F
                                  F
                                                         N                       CF3
                                                              O
                                                                  CH3


 rolipoltidum
 rolipoltide               protein derived from two major allergens of Cryptomeria japonica
                           pollen: Sugi basic protein (Cry j 1) and the polygalacturonase
                           (Cry j 2):
                           (Cry j 1-(213-225)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(108-120)-
                           peptidyl)-L-arginyl-L-arginyl(Cry j 2-(191-209)-peptidyl)-L-arginyl-
                           L-arginyl(Cry j 2-(88-107)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(80-95)-
                           peptidyl)-L-arginyl(Cry j 2-(75-89)-peptide)

 rolipoltide               protéine dérivée de deux principaux allergènes de pollen du cèdre
                           du Japon, Cryptomeria japonica, la protéine basique Sugi (Cry j 1) et
                           la polygalacturonase (Cry j 2) :
                           (Cry j 1-(213-225)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(108-120)-
                           peptidyl)-L-arginyl-L-arginyl(Cry j 2-(191-209)-peptidyl)-L-arginyl-
                           L-arginyl(Cry j 2-(88-107)-peptidyl)-L-arginyl-L-arginyl(Cry j 1-(80-95)-
                           peptidyl)-L-arginyl(Cry j 2-(75-89)-peptide)

 rolipoltida               proteína derivada de dos de los alérgenos principales del polen del
                           cedro de Japón,Cryptomeria japonica : la proteína básica Sugi
                           (Cry j 1) y la poligalacturonasa (Cry j 2) :
                           (Cry j 1-(213-225)-peptidil)-L-arginil-L-arginil(Cry j 1-(108-120)-
                           peptidil)-L-arginil-L-arginil(Cry j 2-(191-209)-peptidil)-L-arginil-
                           L-arginil(Cry j 2-(88-107)-peptidil)-L-arginil-L-arginil(Cry j 1-(80-95)-
                           peptidil)-L-arginil(Cry j 2-(75-89)-péptido)

                           C561H887N169O136S4

                           MKVTVAFNQF GPNRRVFIKR VSNVIIHGRR IDIFASKNFH 40
                           LQKNTIGTGR RWKNNRIWLQ FAKLTGFTLM GRRLKMPMYI 80
                           AGYKTFDGRR VDGIIAAYQN PASWK                105

 romidepsinum
 romidepsin                (1S,4S,10S,16E,21R)-7-[(2Z)ethylidene]-4,21-diisopropyl-2-oxa-
                           12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-
                           3,6,9,19,22-pentone

 romidepsine               (1S,4S,7Z,10S,16E,21R)-7-éthylidène-4,21-bis(1-méthyléthyl)-2-oxa-
                           12,13-dithia-5,8,20,23-tétraazabicyclo[8.7.6]tricos-16-ène-
                           3,6,9,19,22-pentone

 romidepsina               (1S,4S,10S,16E,21R)-7-[(2Z)etilideno]-4,21-diisopropil-2-oxa-
                           12,13-ditia-5,8,20,23-tetraazabiciclo[8.7.6]tricos-16-eno-3,6,9,19,22-
                           pentona




224
WHO Drug Information, Vol. 20, No. 3, 2006                                                                 Recommended INN: List 56


                                             C24H36N4O6S2

                                                          H3 C        CH3
                                                                              O
                                                      H               H
                                               H      N
                                                                      N
                                                                      H
                                                       S O
                                               O      NH S                    O        H
                                                                  H
                                             H 3C                 N
                                                                                  O
                                                                          H
                                                           O
                                                               H 3C       CH3



 rotigaptidum
 rotigaptide                                 N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-
                                             D-alanylglycinamide

 rotigaptide                                 acétyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-
                                             D-alanylglycinamide

 rotigaptida                                 acetil-D-tirosil-D-prolil-(4S)-4-hidroxi-D-prolilglicil-D-alanilglicinamida

                                             C28H39N7O9

                                                                          O
                                                                          H           Gly   D-Ala        Gly NH2
                                                O
                                                     D-Tyr       D-Pro    N
                                                                                          OH
                                             H3 C
                                                                                      H



 sapacitabinum
 sapacitabine                                N-[1-(2-cyano-2-deoxy-β-D-arabinofuranosyl]-2-oxo-
                                             1,2-dihydropyrimidin-4-yl}hexadecanamide

 sapacitabine                                N-[1-(2-cyano-2-désoxy-β-D-arabinofuranosyl)-2-oxo-
                                             1,2-dihydropyrimidin-4-yl]hexadécanamide

 sapacitabina                                N-[1-(2-ciano-2-desoxi-β-D-arabinofuranosil]-2-oxo-
                                             1,2-dihidropirimidin-4-il}hexadecanamida

                                             C26H42N4O5

                                                                                                O

                                                                                                     NH

                                                                                                N

                                                                              HO            O        N
                                                                                            O
                                                                                                NC

                                             H3C
                                                                                          OH




                                                                                                                                225
Recommended INN: List 56                                  WHO Drug Information, Vol. 20, No. 3, 2006


 simotaxelum
 simotaxel                 1,7β-dihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,10β,13α-tetrayl
                           4-acetate 2-benzoate 10-cyclopentanecarboxylate 13-{(2R,3R)-2-
                           hydroxy-3-(isopropoxycarbonyl)amino]-3-(thiophen-2-yl)propanoate}

 simotaxel                 12b-acétate 12-benzoate 6-cyclopentanecarboxylate et 9-[(2R,3R)-
                           2-hydroxy-3-[[(1-méthyléthoxy)carbonyl]amino]-3-(thiophén-
                           2-yl)propanoate] de (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,11-
                           dihydroxy-4a,8,13,13-tétraméthyl-5-oxo-
                           2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodécahydro-7,11-méthano-
                           1H-cyclodéca[3,4]benz[1,2-b]oxète-6,9,12,12b-tétrayle

 simotaxel                 12b-acetato 12-benzoato 6-ciclopentanocarboxilato y 9-[(2R,3R)-2-
                           hidroxi-3-[[(1-metiletoxi)carbonil]amino]-3-(tiofen-2-il)propanoato] de
                           (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,11-dihidroxi-4a,8,13,13-
                           tetrametil-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahidro-
                           7,11-metano-1H-ciclodeca[3,4]benz[1,2-b]oxeto-6,9,12,12b-tetrailo

                           C46H57NO15S


                                                               O
                                                               H       O
                                                          O                   OH
                                                   H3C
                                S HO H                                     CH3 H

                                                  O                CH3
                                                                                   H     H
                                                  H                CH3
                                HN    H       O
                                          O                                    O         O
                                                              OH       H
                                  O
                                                                   O O             CH3
                                          CH3
                               H3C                            O



 sitagliptinum
 sitagliptin               (3R)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5H-
                           [1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one

 sitagliptine              7-[(3R)-3-amino-4-(2,4,5-trifluorophényl)butanoyl]-3-(trifluorométhyl)-
                           5,6,7,8-tétrahydro-1,2,4-triazolo[4,3-a]pyrazine

 sitagliptina              7-[(3R)-3-amino-4-(2,4,5-trifluorofenil)butanoil]-3-(trifluorometil)-
                           5,6,7,8-tetrahidro-1,2,4-triazolo[4,3-a]pirazina

                           C16H15F6N5O

                                  F
                           F
                                              H   NH2 O
                                                                       N
                                                          N
                                                                           N
                                  F                                N

                                                                       CF3




226
WHO Drug Information, Vol. 20, No. 3, 2006                                              Recommended INN: List 56


 sontuzumabum
 sontuzumab                                  immunoglobulin G1, anti-(human episialin) (mouse monoclonal
                                             HMFG-1 γ1-chain), disulfide with mouse monoclonal HMFG-1, dimer

 sontuzumab                                  immunoglobuline G1, anti-(épisialine, spécifique de l'épitope
                                             APDTR) ; dimère du disulfure entre la chaîne γ1 et la chaîne légère
                                             de l'anticorps monoclonal de souris HMFG-1

 sontuzumab                                  inmunoglobulina G1, anti-(human episialina) dímero del disulfuro
                                             entre la cadena HMFG-1 γ1 monoclonal de ratón y la cadena ligera
                                             HMFG-1 monoclonal de ratón



 sotirimodum
 sotirimod                                   2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-
                                             4-amine

 sotirimod                                   2-méthyl-1-(2-méthylpropyl)-1H-imidazo[4,5-c][1,5]naphtyridin-
                                             4-amine

 sotirimod                                   2-metil-1-(2-metilpropil)-1H-imidazo[4,5-c][1,5]naftiridin-4-amina

                                             C14H17N5

                                             H3C
                                                            CH3
                                             H3C        N
                                                N           N


                                                        N   NH2


 stamulumabum*
 stamulumab                                  immunoglobulin G1, anti-(human growth differentiation factor 8)
                                             (human MYO-029 heavy chain), disulfide with human MYO-029
                                             λ-chain, dimer

 stamulumab                                  immunoglobuline G1, anti-(facteur 8 de croissance/différenciation
                                             (GDF-8 ou myostatine) humain) ; dimère du disulfure entre la chaîne
                                             lourde et la chaîne λ de l’anticorps monoclonal humain MYO-029

 estamulumab                                 inmunoglobulina G1, anti-(factor 8 de diferenciación del crecimiento
                                             humano) dímero del disulfuro entre la cadena pesada de MYO-029
                                             humano y la cadena λ de MYO-029 humano

                                             C6330H9748N1672O1998S48



 tadocizumabum*
 tadocizumab                                 immunoglobulin G1, anti-(human integrin αIIbβ3) Fab fragment
                                             (human-mouse monoclonal C4G1 γ1-chain), disulfide with human-
                                             mouse monoclonal C4G1 κ-chain

 tadocizumab                                 immunoglobuline G1, anti-(intégrine αIIbβ3 humaine), disulfure entre
                                             la chaîne γ1 et la chaîne κ du fragment Fab de l’anticorps
                                             monoclonal de souris C4G1 humanisé




                                                                                                                   227
Recommended INN: List 56                               WHO Drug Information, Vol. 20, No. 3, 2006


 tadocizumab               inmunoglobulina G1, anti-(integrina humana αIIbβ3) disulfuro entre
                           el fragmento Fab de la C4G1 cadena γ1 del anticuerpo monoclonal
                           hombre-ratón, y la cadena κ del anticuerpo monoclonal hombre-
                           ratón C4G1

                           C2107H3252N562O673S12

                                                                    QVQLVQSGAE      VKKPGSSVKV
                           DIQMTQTPST          LSASVGDRVT           SCKASGYAFT      NYLIEWVRQA
                           ISCRASQDIN          NYLNWYQQKP           PGQGLEWIGV      IYPGSGGTNY
                           GKAPKLLIYY          TSTLHSGVPS           NEKFKGRVTL      TVDESTNTAY
                           RFSGSGSGTD          YTLTISSLQP           MELSSLRSED      TAVYFCARRD
                           DDFATYFCQQ          GNTLPWTFGQ           GNYGWFAYWG      QGTLVTVSSA
                           GTKVEVKRTV          AAPSVFIFPP           STKGPSVFPL      APSSKSTSGG
                           SDEQLKSGTA          SVVCLLNNFY           TAALGCLVKD      YFPEPVTVSW
                           PREAKVQWKV          DNALQSGNSQ           NSGALTSGVH      TFPAVLQSSG
                           ESVTEQDSKD          STYSLSSTLT           LYSLSSVVTV      PSSSLGTQTY
                           LSKADYEKHK          VYACEVTHQG           ICNVNHKPSN      TKVDKKVEPK
                           LSSPVTKSFN          RGEC                 SCDKTH



 talotrexinum
 talotrexin                2-{[(4S)-4-carboxy-4-(4-{[(2,4-diaminopteridin-6-yl)methyl]=
                           amino}benzamido)butyl]carbamoyl}benzoic acid

 talotrexine               acide 2-[[(4S)-4-carboxy-4-[[4-[[(2,4-diaminoptéridin-6-yl)méthyl]=
                           amino]benzoyl]amino]butyl]carbamoyl]benzoïque

 talotrexina               ácido 2-[[(4S)-4-carboxi-4-[[4-[[(2,4-diamino-6-pteridinil)metil]=
                           amino]benzoil]amino]butil]carbamoil]benzoico

                           C27H27N9O6

                                                                O    H   CO2H

                                     NH2                            N
                                                                    H           H
                                           N                                    N
                                 N                 N
                                                   H
                                                                                    O   CO2H
                           H2N       N     N



 telaprevirum
 telaprevir                (1S,3aR,6aS)-2-[(2S)-2-{(2S)-cyclohexyl[(pyrazin-
                           2-ylcarbonyl)amino]acetamido}-3,3-dimethylbutanoyl]-
                           N-{(3S)-1-cyclopropylamino)-1,2-dioxohexan-
                           3-yl}octahydrocyclopenta[c]pyrrole-1-carboxamide

 télaprévir                (1S,3aR,6aS)-2-[(2S)-2-[[(2S)-cyclohexyl[(pyrazinylcarbonyl)amino]=
                           étyl]amino]-3,3-diméthylbutanoyl]-N-[(1S)-1-[(cyclopropylamino)=
                           oacétyl]butyl]octahydrocyclopenta= [c]pyrrole-1-carboxamide

 telaprevir                1S,3aR,6aS)-2-[(2S)-2-[[(2S)-ciclohexil[(pirazinilcarbonil)amino]=
                           acetil]amino]-3,3-dimetilbutanoil]-N-[(1S)-1-[(ciclopropilamino)=
                           oxoacetil]butil]octahidrociclopenta[c]pirrol-1carboxamida




228
WHO Drug Information, Vol. 20, No. 3, 2006                                                             Recommended INN: List 56


                                             C36H53N7O6

                                                                               CH3
                                                                    H3C             H
                                                                                CH3
                                                    N               O
                                                            H                   H                        O
                                             N              N                       N         H                   H
                                                                        N                    HN                   N
                                                                        H
                                                        O       H               O       H
                                                                                             O     H          O

                                                                                                        CH3


 tiplasininum
 tiplasinin                                  2-{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indole-3-yl}-
                                             2-oxoacetic acid

 tiplasinine                                 acide [1-benzyl-5-[4-(triflorométhoxy)phényl]-1H-indol-
                                             3-yl]oxoacétique

 tiplasinina                                 ácido 2-{1-bencil-5-[4-(trifluorometoxi)fenil]-1H-indol-3-il}-
                                             2-oxoacético

                                             C24H16F3NO4

                                                                O
                                                                        CO2H


                                                            N

                                                                                            OCF3


 tramiprosatum
 tramiprosate                                3-aminopropane-1-sulfonic acid

 tramiprosate                                acide 3-aminopropane-1-sulfonique

 tramiprosato                                ácido 3-aminopropano-1-sulfónico

                                             C3H9NO3S

                                             H2 N               SO3H


 transferrinum aldifitoxum
 transferrin aldifitox                       a conjugate of the precursor of human serotransferrin (siderophillin)
                                             with a primary amine group used to form an amidine with
                                             (4-iminobutane-1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine-
                                             1,3-diyl]-1,3-phenylenecarbonyl and forming an N-benzoyl derivative
                                             of a primary amine group of diphtheria [550-L-phenylalanine]toxin
                                             from Corynebacterium diphtheriae-(26-560)-peptide

 transferrine aldifitox                      précurseur de la sérotransferrine humaine (sidérophilline) dont
                                             une fonction amine primaire est liée par une fonction
                                             carboximidamide (amidine) au pont (4-iminobutane-
                                             1,4-diyl)sulfanediyl[(3RS)-2,5-dioxopyrrolidine -1,3-diyl]-
                                             1,3-phénylènecarbonyl lui-même lié par une fonction benzamide
                                             à une amine primaire du [550-L-phénylalanine]toxine diphtérique
                                             de Corynebacterium diphteriae-(26-560)-peptide




                                                                                                                            229
Recommended INN: List 56                             WHO Drug Information, Vol. 20, No. 3, 2006




 transferrina aldifitox    precursor de la serotransferrina humana (siderofilina) en el cual
                           una función amina primaria está ligada por una función
                           carboximidamida (amidina) al puente (4-iminobutano-
                           1,4-diil)sulfanodiil[(3RS)-2,5-dioxopirrolidina-1,3-diil]-
                           1,3-fenilenocarbonil ligado a su vez por una función benzamida
                           una amina primaria de la [550-L-fenilalanina]toxina diftérica del
                           Corynebacterium diphteriae-(26-560)-péptido

                           C5992H9317N1641O1834S63

                                                          O
                                                                               NH CRM107      and epimer at C*
                                                              N
                                                                                              et l'épimère en C*
                                     Tf NH                *                O                  y el epímero al C*
                                                     S            O
                                                          H
                                             NH

                                  Tf-NH2=    MRLAVGALLV   CAVLGLCLAV           PDKTVRWCAV      SEHEATKCQS
                                             FRDHMKSVIP   *
                                                          SDGPSVACVK           KASYLDCIRA      IAANEADAVT
                                             LDAGLVYDAY   LAPNNLKPVV           AEFYGSKEDP      QTFYYAVAVV
                                             KKDSGFQMNQ   LRGKKSCHTG           LGRSAGWNIP      IGLLYCDLPE
                                             PRKPLEKAVA   NFFSGSCAPC           ADGTDFPQLC      QLCPGCGCST
                                             LNQYFGYSGA   FKCLKDGAGD           VAFVKHSTIF      ENLANKADRD
                                             QYELLCLDNT   RKPVDEYKDC           HLAQVPSHTV      VARSMGGKED
                                             LIWELLNQAQ   EHFGKDKSKE           FQLFSSPHGK      DLLFKDSAHG
                                             FLKVPPRMDA   KMYLGYEYVT           AIRNLREGTC      PEAPTDECKP
                                             VKWCALSHHE   RLKCDEWSVN           SVGKIECVSA      ETTEDCIAKI
                                             MNGEADAMSL   DGGFVYIAGK           CGLVPVLAEN       *
                                                                                               YNKSDNCEDT
                                             PEAGYFAVAV   VKKSASDLTW           DNLKGKKSCH      TAVGRTAGWN
                                             IPMGLLYNKI   NHCRFDEFFS           EGCAPGSKKD      SSLCKLCMGS
                                             GLNLCEPNNK   EGYYGYTGAF           RCLVEKGDVA      FVKHQTVPQN
                                             TGGKNPDPWA   KNLNEKDYEL           LCLDGTRKPV      EEYANCHLAR
                                             APNHAVVTRK   DKEACVHKIL                    *
                                                                               RQQQHLFGSN      VTDCSGNFCL
                                             FRSETKDLLF   RDDTVCLAKL           HDRNTYEKYL      GEEYVKAVGN
                                             LRKCSTSSLL   EACTFRRP
                                                              * glycosylation sites
                                                              * sites de glycosylation
                                                              * posiciónes de glicosilación


                           H2N-CRM107=      GADDVVDSSK    SFVMENFSSY        HGTKPGYVDS        IQKGIQKPKS
                                            GTQGNYDDDW    KGFYSTDNKY        DAAGYSVDNE        NPLSGKAGGV
                                            VKVTYPGLTK    VLALKVDNAE        TIKKELGLSL        TEPLMEQVGT
                                            EEFIKRFGDG    ASRVVLSLPF        AEGSSSVEYI        NNWEQAKALS
                                            VELEINFETR    GKRGQDAMYE        YMAQACAGNR        VRRSVGSSLS
                                            CINLDWDVIR    DKTKTKIESL        KEHGPIKNKM        SESPNKTVSE
                                            EKAKQYLEEF    HQTALEHPEL        SELKTVTGTN        PVFAGANYAA
                                            WAVNVAQVID    SETADNLEKT        TAALSILPGI        GSVMGIADGA
                                            VHHNTEEIVA    QSIALSSLMV        AQAIPLVGEL        VDIGFAAYNF
                                            VESIINLFQV    VHNSYNRPAY        SPGHKTQPFL        HDGYAVSWNT
                                            VEDSIIRTGF    QGESGHDIKI        TAENTPLPIA        GVLLPTIPGK
                                            LDVNKSKTHI    SVNGRKIRMR        CRAIDGDVTF        CRPKSPVYVG
                                            NGVHANLHVA    FHRSSSEKIH        SNEISSDSIG        VLGYQKTVDH
                                            TKVNFKLSLF    FEIKS




230
WHO Drug Information, Vol. 20, No. 3, 2006                                              Recommended INN: List 56


 tucotuzumabum celmoleukinum*
 tucotuzumab celmoleukin                     immunoglobulin G1, anti-(tumor associated calcium signal
                                             transducer 1 (KS 1/4 antigen)) (human-mouse monoclonal huKS-IL2
                                             heavy chain) fusion protein with interleukin 2 (human), disulfide with
                                             human-mouse monoclonal huKS-IL2 light chain, dimer

 tucotuzumab celmoleukine                    immunoglobuline G1, anti-(transducteur 1 du signal calcique associé
                                             aux cellules tumorales humaines), dimère du disulfure entre le
                                             peptide de fusion de la chaîne lourde, de l’anticorps monoclonal de
                                             souris huKS-IL2 humanisé, avec l’interleukine 2 humaine, et la
                                             chaîne légère de l’anticorps monoclonal de souris huKS-IL2
                                             humanisé

 tucotuzumab celmoleukina                    inmunoglobulina G1, anti-(antígeno 17-1A humano) dímero del
                                             disulfuro entre la proteína de fusión de la cadena pesada del
                                             anticuerpo monoclonal huKS-IL2 hombre-ratón y la interleukina 2
                                             (humana), y la cadena ligera del anticuerpo monoclonal huKS-IL2
                                             hombre-ratón

                                             C7812H12114N2042O2406S60




 velaferminum*
 velafermin                                  fibroblast growth factor 20 (human recombinant CG53135)

 vélafermine                                 facteur-20 de croissance du fibroblaste humain recombinant
                                             (CG53135)

 velafermina                                 factor 20 de crecimiento de fibroblastos (recombinante humano
                                             CG53135)

                                             C1047H1632N306O302S5

                                             MAPLAEVGGF        LGGLEGLGQQ       VGSHFLLPPA        GERPPLLGER
                                             RSAAERSARG        GPGAAQLAHL       HGILRRRQLY        CRTGFHLQIL
                                             PDGSVQGTRQ        DHSLFGILEF       ISVAVGLVSI        RGVDSGLYLG
                                             MNDKGELYGS        EKLTSECIFR       EQFEENWYNT        YSSNIYKHGD
                                             TGRRYFVALN        KDGTPRDGAR       SKRHQKFTHF        LPRPVDPERV
                                             PELYKDLLMY        T


 verpasepum caltespenum*
 verpasep caltespen                          60 kDa chaperonin 2 (HSP 65 from Mycobacterium bovis strain
                                             BCG) fusion protein with L-histidylprotein E7 from human
                                             papillomavirus type 16

 verpasep caltespen                          60 kDa chaperonine 2 (HSP 65 de Mycobacterium bovis souche
                                             BCG) protéine de fusion avec la L-histidylprotéine E7 de
                                             papillomavirus de type 16 humain

 verpasep caltespeno                         60 kDa chaperonina 2 (HSP 65 de Mycobacterium bovis cepa BCG)
                                             proteína de fusión con la L-histidilproteína E7 del papilomavirus
                                             humano 16




                                                                                                                 231
Recommended INN: List 56                                 WHO Drug Information, Vol. 20, No. 3, 2006


                           C2959H4860N810O965S16

                            AKTIAYDEEA         RRGLERGLNA         LADAVKVTLG         PKGRNVVLEK
                           KWGAPTITND          GVSIAKEIEL         EDPYEKIGAE         LVKEVAKKTD
                           DVAGDGTTTA          TVLAQALVRE         GLRNVAAGAN         PLGLKRGIEK
                            AVEKVTETLL         KGAKEVETKE         QIAATAAISA         GDQSIGDLIA
                           EAMDKVGNEG          VITVEESNTF         GLQLELTEGM         RFDKGYISGY
                           FVTDPERQEA          VLEDPYILLV         SSKVSTVKDL         LPLLEKVIGA
                           GKPLLIIAED          VEGEALSTLV         VNKIRGTFKS         VAVKAPGFGD
                           RRKAMLQDMA         ILTGGQVISE          EVGLTLENAD         LSLLGKARKV
                            VVTKDETTIV         EGAGDTDAIA         GRVAQIRQEI         ENSDSDYDRE
                           KLQERLAKLA          GGVAVIKAGA         ATEVELKERK         HRIEDAVRNA
                           KAAVEEGIVA          GGGVTLLQAA         PTLDELKLEG         DEATGANIVK
                            VALEAPLKQI         AFNSGLEPGV         VAEKVRNLPA         GHGLNAQTGV
                           YEDLLAAGVA         DPVKVTRSAL          QNAASIAGLF         LTTEAVVADK
                           PEKEKASVPG          GGDMGGMDFH         MHGDTPTLHE         YMLDLQPETT
                           DLYCYEQLND         SSEEEDEIDG          PAGQAEPDRA         HYNIVTFCCK
                           CDSTLRLCVQ         STHVDIRTLE          DLLMGTLGIV         CPICSQKP



 vicrivirocum
 vicriviroc                (4,6-dimethylpyrimidin-5-yl){4-[(3S)-4-{(1R)-2-methoxy-
                           1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-
                           4-methylpiperidin-1-yl}methanone

 vicriviroc                1-[(4,6-diméthylpyrimidin-5-yl)carbonyl]-4-[(3S)-4-[(1R)-2-méthoxy-
                           1-[4-(trifluorométhyl)phényl]éthyl]-3-méthylpipérazin-1-yl]-
                           4-méthylpipéridine

 vicriviroc                (4,6-dimetilpirimidin-5-il){4-[(3S)-4-{(1R)-2-metoxi-
                           1-[4-(trifluorometil)fenil]etil}-3-metilpiperazin-1-il]-4-metilpiperidin-
                           1-il}metanona

                           C28H38F3N5O2

                                                                      CH3
                                                 H3C     H H      O

                                                          N
                               N     CH3           N
                                                                            CF3
                                                   CH3
                           N             N

                               CH3   O



 vorinostatum
 vorinostat                N-hydroxy-N'-phenyloctanediamide

 vorinostat                N-hydroxy-N'-phényloctanediamide

 vorinostat                N-hidroxi-N'-feniloctanodiamido




232
WHO Drug Information, Vol. 20, No. 3, 2006                                                       Recommended INN: List 56


                                             C14H20N2O3

                                                                   O
                                                                                        H
                                                                                        N
                                                              N                             OH
                                                              H
                                                                                    O



 zibotentanum
 zibotentan                                  N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-
                                             2-yl)phenyl]pyridine-3-sulfonamide

 zibotentan                                  N-(3-méthoxy-5-méthylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-
                                             2-yl)phényl]pyridine-3-sulfonamide

 zibotentán                                  N-(3-metoxi-5-metilpirazin-2-il)-2-[4-(1,3,4-oxadiazol-
                                             2-il)fenil]piridine-3-sulfonamida

                                             C19H16N6O4S

                                                          N



                                              O       S                     N
                                                          NH
                                                  O                             N
                                                                   OCH3 O
                                                      N
                                                               N

                                                          CH3



 zotarolimusum
 zotarolimus                                 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             9,27-dihydroxy-10,21-dimethoxy-3-{(2R)-1-[(1S,3R,4S)-3-methoxy-
                                             4-(1H-tetrazol-1-yl)cyclohexyl]propan-2-yl}-6,8,12,14,20,26-
                                             hexamethyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-
                                             octadecahydro-5H-23,27-epoxypyrido[2,1-
                                             c][1,4]oxaazahentriacontine-1,5,11,28,29(6H,31H)-pentone

 zotarolimus                                 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             9,27-dihydroxy-10,21-diméthoxy-3-[(1R)-2-[(1S,3R,4S)-3-méthoxy-
                                             4-(1H-tétrazol-1-yl)cyclohexyl]-1-méthyléthyl]-6,8,12,14,20,26-
                                             hexaméthyl-3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-
                                             octadécahydro-23,27-époxy-5H-pyrido[2,1-
                                             c][1,4]oxazahentriacontine-1,5,11,28,29(6H,31H)-pentone

 zotarolimus                                 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-
                                             9,27-dihidroxi-10,21-dimetoxi-3-{(2R)-1-[(1S,3R,4S)-3-metoxi-
                                             4-(1H-tetrazol-1-il)ciclohexil]propan-2-il}-6,8,12,14,20,26-hexametil-
                                             3,4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-
                                             octadecahidro-5H-23,27-epoxipirido[2,1-c][1,4]oxaazahentriacontina-
                                             1,5,11,28,29(6H,31H)-pentona




                                                                                                                      233
Recommended INN: List 56                                                        WHO Drug Information, Vol. 20, No. 3, 2006


                                              C52H79N5O12

                                                      N
                                                 N
                                                  N N         H

                                                  H
                                               H3CO
                                                                      H
                                                                          CH3
                                                          O               H O        H OH
                                                      H           H                              O
                                                                  O
                                                                                     H
                                                      N           O         H3C H CH3 OCH3
                                                                                 CH3
                                                                  OH      H            H3C H
                                                                    O                                 H
                                                      O
                                                                                                     CH3
                                                          H                  H OCH3
                                                          H3C




* Electronic structure available on Mednet: http://mednet.who.int/
* Structure électronique disponible sur Mednet: http://mednet.who.int/
* Estructura electrónica disponible en Mednet: http://mednet.who.int/



234
    WHO Drug Information, Vol. 20, No. 3, 2006                                               Recommended INN: List 56




                                 AMENDMENTS TO PREVIOUS LISTS
                         MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                             MODIFICACIONES A LAS LISTAS ANTERIORES


    Recommended International Nonproprietary Names (Rec. INN): List 21
    Dénominations communes internationales recommandées (DCI Rec.): Liste 21
    Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 21
    (WHO Drug Information, Vol. 35, No. 5, 1981)

    p. 4     delete/supprimer/suprímase     insert/insérer/insertése
             docusatum natricum             natrii docusas



    Recommended International Nonproprietary Names (Rec. INN): List 54
    Dénominations communes internationales recommandées (DCI Rec.): Liste 54
    Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 54
    (WHO Drug Information, Vol. 19, No. 3, 2005)

    p. 253   suprímase                      insertése
             epoetina zeta                  epoetina dseta




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




                                                                                                                    235
